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Abstract
The aim of this study was to investigate the mechanism through which Sphingosine kinase-1 (SPHK1) exerts its anti-
apoptosis activity in glioma cancer cells. We here report that dysregulation of SPHK1 alters the sensitivity of glioma to
apoptosis both in vitro and in vivo. Further mechanistic study examined the expression of Bcl-2 family members, including
Bcl-2, Mcl-1, Bax and Bim, in SPHK1-overexpressing glioma cells and revealed that only pro-apoptotic Bim was
downregulated by SPHK1. Moreover, the transcriptional level of Bim was also altered by SPHK1 in glioma cells. We next
confirmed the correlation between SPHK1 and Bim expression in primary glioma specimens. Importantly, increasing SPHK1
expression in glioma cells markedly elevated Akt activity and phosphorylated inactivation of FOXO3a, which led to
downregulation of Bim. A pharmacological approach showed that these effects of SPHK1 were dependent on
phosphatidylinositol 3-kinase (PI3K). Furthermore, effects of SPHK1 on Akt/FOXO3a/Bim pathway could be reversed by
SPHK1 specific RNA interference or SPHK1 inhibitor. Collectively, our results indicate that regulation of the Akt/FOXO3a/Bim
pathway may be a novel mechanism by which SPHK1 protects glioma cells from apoptosis, thereby involved in glioma
tumorigenesis.
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Introduction
Glioma is the most common form of primary brain tumors [1].
The low overall survival rate of glioma patients has remained
unchanged over decades despite that many efforts have been made
in improving the treatment of glioma. Impairments in apoptotic
programs are tightly linked to the failure of clinical cancer therapy,
such as chemotherapy and radiotherapy, and thus, rational
development of more efficacious anti-glioma therapies will largely
rely on revealing mechanisms involved in regulating the apoptotic
programs in glioma cells [2–4].
SPHK1, an oncogenic enzyme, has been found to induce a
transforming phenotype in fibroblasts and tumor formation in
nude mice [5,6]. It was also found that in a variety of tumor types,
including glioma, SPHK1 mRNA and protein were significantly
elevated [7–10]. The oncogenic function of SPHK1 has been
linked to deregulated apoptotic pathways, as ectopic expression of
SPHK1 could promote cell proliferation and induce resistance to
apoptosis [11]. The molecular mechanism underlying the above
oncogenic features of SPHK1, however, remains largely unknown.
Forkhead box O (FOXO) transcription factors are a subfamily
of forkhead proteins characterized by a ‘winged-helix’ DNA-
binding domain termed the forkhead box [12]. It has been
documented that members of the FOXO subfamily are involved
in various signaling pathways and modulate a wide range of
biochemical processes, such as cell cycle progression, differentia-
tion, DNA damage repair, and programmed cell death [13].
FOXO family proteins regulate cell survival by transcriptionally
modulating the expression of death receptor ligands and Bim, a
pro-apoptotic protein belongs to the BH3-only subgroup of BCL-2
family [14,15]. The transcriptional activity of FOXO3a is
regulated by the phosphorylation status mediated by Akt kinase,
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including gliomas [16–18]. Upon stimulation of the PI3K/Akt
signaling cascade, the phosphorylated FOXO3a proteins bind to
the 14-3-3 proteins in the nucleus and are subsequently exported
from the nucleus immediately, thereby inhibiting FOXO3a-
dependent transcription. Conversely, inactivation of Akt activity
results in FOXO3a dephosphorylation, nuclear translocation, and
enhanced transcription of target genes [15]. Interestingly, it has
been demonstrated that upregulation of SPHK1 could induce
resistance to apoptosis by a mechanism involving activation of the
PI3K/Akt pathway in HS1 erythroleukemic cells [19].
In the current study, we report that SPHK1 overexpression
suppressed apoptosis induced by UV radiation or adriamycin via
downregulation of Bim. Such effects of SPHK1 were further
confirmed by shRNA-mediated knockdown experiments. Further-
more, we demonstrated that downregulation of Bim was mediated
by Akt activation, which subsequently induced phosphorylation
and inactivation of FOXO3a in glioma cells. Taken together, our
results suggest that the PI3K/Akt/FOXO3a/Bim axis might
constitute a signaling cascade that mediates the anti-apoptotic
activity of SPHK1 in glioma cells and thereby play an essential
role in the development and progression of glioma, as well as in its
insensitivity to pro-apoptotic therapies.
Materials and Methods
Ethics Statement
Glioma tissues. A total of 82 paraffin-embedded glioma
samples, which had been clinically and histologically diagnosed at
the First Affiliated Hospital of Sun Yat-sen University during year
of 2000 to 2002, were obtained with prior written informed
consents from the patients and approval from the Institutional
Research Ethics Committees of Sun Yat-sen University and its
First Affiliated Hospital. Clinical and clinicopathologic
classification and staging were determined according to the
World Health Organization (WHO) [20]. Clinical information
on the samples is summarized as described previously by us,
including 11 cases of WHO grade I, 21 cases of WHO grade II, 30
cases of WHO grade III, and 20 cases of WHO grade IV tumors.
Cell lines and treatments
Glioma cell lines U87MG and LN-382 were kindly provided by
Dr. Shi-Yuan Cheng at the Department of Pathology, University
of Pittsburg, and maintained in DMEM supplemented with 10%
FBS [21]. In some experiments, adriamycin (Sigma, St. Louis,
MO), LY294002 (Cell Signaling, Beverly, MA), or sphingosine
kinase inhibitor (2-(p-Hydroxyanilino)-4-(p-chlorophenyl) thiazole,
SK-I) (Calbiochem, La Jolla, CA) dissolved in dimethyl sulfoxide
(DMSO), was used to treat cells at indicated final concentrations
and times.
Vectors and retroviral infection
SPHK1 construct was generated by sub-cloning PCR- amplified
full-length human SPHK1 cDNA into pMSCV. For depletion of
SPHK1, two human siRNA sequences were cloned into pSuper-
retro-puro to generate pSuper-retro-SPHK1-RNAi(s), respective-
ly, and the sequences are RNAi#1: GGCTGAA ATCTCCTT-
CACG; RNAi#2: GGGCAAGGCCTTGCAGCTC. Retroviral
production and infection were performed as described previously
[21,22].
Western blotting (WB)
Western blotting was performed according to standard methods
as described previously [20]. The following primary antibodies
were used: anti-SPHK1 (Abcam, Cambridge, MA), anti-poly
ADP-ribose polymerase (PARP), anti-caspase-3, anti-Bcl-2, anti-
Mcl-1, anti-Bax, anti-Bim, , anti-FOXO3a anti-phospho-
FOXO3a (Ser
253), anti-phospho-Akt (Thr
308), anti-phospho-Akt
(Ser
473), anti-total Akt (Cell Signaling, Beverly, MA), and anti-a-
tubulin (Sigma-Aldrich, St Louis, MO). The nuclear extracts were
prepared using the Nuclear Extraction kit (Active Motif, Tokyo,
Japan) as the manufacturer instructed.
Sphingosine Kinase Activity Assay
The activity of sphingosine kinase was quantified by using a
commercial Sphingosine Kinase Activity Assay Kit (Echelon
Biosciences, Salt Lake City, UT) as the manufacturer instructed.
Cell survival assay
Cells were plated in six-well plates at density of 1610
5 cells/well
and incubated for 24 h, followed by adriamycin treatment (0.5, 1.0
or 2.0 mM) or irradiation with UV245 nm (20, 40, 60 J/m
2) and
further incubation for 72 h. Numbers of surviving cells were
determined by the trypan blue exclusion method.
TUNEL assay
The DeadEnd
TM Fluorometric TUNEL System (Promega,
Madison, WI) was used for TUNEL assay according to the
manufacturer’s instruction.
Annexin-V binding assay
The ApopNexin
TM FITC Apoptosis Detection Kit (Millipore,
Lake Placid, NY) was used to quantitatively examine apoptotic
cells according to manufacturer’s instruction.
Subcutaneous xenograft mouse model
Animal protocols were approved by the Ethical Committee of
Sun Yat-sen University. Nude mice were injected s.c. with 2610
6
cells (U87MG/vector, U87MG/SPHK1, U87MG/RNAi vector
and U87MG-SPHK1-RNAi) in 0.1 mL of PBS in the right flank.
When the tumor size reached approximately 50 mm
3, the mice
were injected i.p. every 3 d with 5 mg/kg epirubicin (49-
epidoxorubicin, Pfizer, New York, NY), an antineoplastic agent
derived from adriamycin, dissolved in saline. In another set of
experiment, nude mice were injected s.c. with 2610
6 cells
(U87MG-vector) in 0.1 mL of PBS in the right flank. When the
tumor size reached to 50 mm
3, the mice were randomized into
two groups (n=5) and injected intraperitoneally either with
epirubicin (5 mg/kg) or epirubicin(5 mg/kg) plus SK1-I (50 mg/
kg) every 3 days, up to 15days. Tumor volumes were measured
with caliper and calculated using formula: 0.526(length in
millimeters)6(width in millimeters)
2. At the end of the
experiment, tumors were excised, fixed in formalin and embedded
in paraffin.
RNA extraction and real-time RT-PCR
RNA extraction, RT and real-time PCR were performed as
described previously [9]. The primers selected are as the following:
Bim, forward: 59-TATGAGAAG ATCCTCCCTGC-39 and
reverse: 59-ATATCTGCAGGTTCAGCC TG-39; GAPDH, for-
ward: 59-ACCACAGTCCATGCCATCAC-39 and reverse: 59-
TCCACCACCCTG TTGCTGTA-39.
Luciferase activity assay
Dual-Luciferase reporter assays were performed according to
the manufacturer’s instructions (Promega, Madison, WI). Briefly,
5610
4 cells were seeded in triplicates in 24-well plates and allowed
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plasmid or control-luciferase plasmid plus 10 ng pRL-TK renilla
plasmid were transfected into the cells using the Lipofectamine
2000 reagent (Invitrogen Co., Carlsbad, CA). Luciferase and
Renilla luciferase activities were determined 48 h after transfection
for each sample according to the manufacturer’s instruction. The
reporter plasmid for quantitatively detecting the transcriptional
activity of FoxO3a was generated essentially as described [23].
Briefly, oligonucleotides containing an array of three copies of an
insulin response sequence (IRS) (59-GCAAAACAAACTTA-
TTTTGAAGCAAAACAAACTTAT TTTGAAGCAAA ACA-
AACT TATTTTGAA-39 and 59-AGCTTTCAAAATAAGT-
TTGTT TTGCTTCAAAA TAAGTTTGTTT TGCTTCAA-
AATAAGTTTGTTTTGCGTAC -39) were annealed to form a
double-stranded oligonucleotide and ligated into the Kpn I and
Hind III sites of the pGL3-Enhancer plasmid (Promega, Madison,
WI) to create pGL3-36IRS.
Immunohistochemistry
Immunohistochemical (IHC) analysis was performed to study
altered protein expression in human glioma tissue. The scores of
SPHK1 and Bim were carried out similarly to previously described
methods [9]. In brief, the degree of immunostaining of SPHK1
and Bim proteins were evaluated and scored independently by two
observers, considering both the proportion of positive staining
tumor cells and the staining intensity. Scores representing the
proportion of positive stained tumor cells was graded as: 0 (no
positive tumor cells), 1 (,10%), 2 (10–50%), and 3 (.50%). The
intensity of staining was determined as: 0 (no staining); 1 (weak
staining=light yellow), 2 (moderate staining=yellow brown), and
3 (strong staining=brown). The staining index (SI) was calculated
as the product of staining intensity and percentage of positive
tumor cells, resulting in scores as 0, 1, 2, 3, 4, 6 and 9. Cutoff
values for SPHK1 were chosen based on a measurement of
heterogeneity using the log-rank test with respect to overall
survival. We identified the optimal cutoff as: the SI score of $4
was considered as high expression, and #3 as low expression.
SiRNA
FOXO3a specific siRNA oligo was purchased from Ribobio
(Guangzhou, China). The sense sequence is 59-
GAGCTCTTGGTGGATCATC-39. SiRNA was transfected into
cells cultured in 6-well plates using Lipofectamine 2000 following
the manufacturer’s instructions (Invitrogen, Carlsbad, CA).
Following transfection with siRNA, cells were cultured for 2 days
before use.
Statistical analysis
All statistical analyses were carried out using the SPSS 11.0
statistical software package. Bivariate correlation between SPHK1
and Bim expression were calculated by Spearmans rank
correlation coefficients. All values represent at least three
independent experiments and are expressed as the means 6
standard deviation (SD). The differences between experimental
conditions were compared on a one-to-one basis using Student’s t
tests. p,0.05 was considered statistically significant.
Results
Dysregulation of SPHK1 altered the apoptotic sensitivity
of glioma cells both in vitro and in vivo
To determine whether dysregulation of SPHK1 in glioma cells
could alter resistance to apoptosis, stable glioma cell lines (U87MG
and LN-382) with SPHK1 overexpression or knockdown were
established (Figures 1A and 2A). The SPHK1 enzymatic activities
in SPHK1 overexpressed glioma cells were markedly increased in
comparison to that in vector-control cells, whereas silencing of
SPHK1 led to significant decrease of SPHK1 activity (Figures 1B
and 2B). As expected, both SPHK1-expressing cell lines showed
stronger resistance to treatment of various doses of UV irradiation
and adriamycin in comparison with the vector-control, which
indicated that overexpression of SPHK1 could significantly
reduced cell death induced by UV irradiation and chemothera-
peutic drug adriamycin (Figures 1C). Furthermore, TUNEL and
Annexin-V binding assays were performed to assess that the
increased viability of SPHK1 overexpressing cells was due to
apoptosis inhibition. As shown in Figure 1D, the number of
apoptotic cells in vector-infected cells was significantly higher than
that in SPHK1-overexpressing cells upon 1.0 mM adriamycin
treatment, suggesting that ectopic expression of SPHK1 protected
glioma cells from pro-apoptotic induction. Moreover, we charac-
terized the effect of SPHK1 on apoptotic protection by examining
the cleavages of pro-caspase 3 and PARP in glioma cells
expressing SPHK1. As shown in Figure 1E, cleavages of both
caspase 3 and PARP were suppressed in the SPHK1-overexpress-
ing cells. In contrast, silencing SPHK1 by RNAi#2, which showed
markedly decreased expression of SPHK1, dramatically enhanced
UV- or adriamycin-induced cell death in glioma cells (Figures 2C).
Results of TUNEL and Annexin-V binding assays indicated that
the decreased viability of SPHK1-downregulated cells was due to
increased apoptosis susceptibility (Figure 2D). In addition,
activating cleavages of PARP and caspase 3 have been shown to
be markedly increased in SPHK1-downregulated cells (Figure 2E).
Taken together, these data suggest that SPHK1 acts to stimulate
survival and anti-apoptotic signaling in glioma cells.
To further confirm the anti-apoptotic potential of SPHK1 in
vivo, we decided to examine whether dysregulation of SPHK1
could alter the sensitivity of glioma cells to apoptosis in nude mice.
When the volume of tumors reached approximately 50 mm
3, the
nude mice were injected intraperitoneally with the adriamycin
analogue epirubicin (5 mg/kg) every 3 days, up to 15days. As
shown in Figures 3A and 3B, the U87MG-SPHK1 cells formed
tumors and displaying larger tumor sizes and higher tumor weights
than those formed by the U87MG-vector control cells. Whereas,
the tumors formed from U87MG-SPHK1-RNAi cells were
smaller, in size and weight, than those of vector control cell-
formed tumors. Furthermore, TUNEL assay indicated that the
percentage of apoptotic cells in U87MG control cell-formed
tumors was significantly higher than that in the tumors formed
from U87MG-SPHK1 cells, but lower than that of the U87MG-
SPHK1-RNAi cell-formed tumors (Figures 3C and 3D). More-
over, the impact of SPHK1 inhibition was examined, using a
specific SPHK1 inhibitor (SK1-I), on the resistance of gliomas to
epirubicin treatment. When U87MG control cells-formed tumors
reached a mean volume of approximately 50,100 mm
3, the nude
mice were randomized into two groups (n=5) and injected
intraperitoneally either with epirubicin (5 mg/kg) or epirubicin
(5 mg/kg) plus SK1-I (50 mg/kg) every 3 days, up to 15days. As
compared with epirubicin treated group, both the tumor sizes and
tumor weights in mice treated by epirubicin plus SK1-I were
dramatically reduced (Figures 3A and 3B). TUNEL assay revealed
that inhibition of SPHK1 activity enhanced epirubicin-induced
apoptosis of glioma cells (Figures 3C and 3D). Taken together, our
results indicate that up-regulation of SPHK1 enhanced the
resistance of glioma cells to cytotoxic reagent-induced cell
apoptosis, and targeting SPHK1 through inhibition of SPHK1
activity might represent a potential therapeutical strategy for
glioma treatment.
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regulated by SPHK1
Bcl-2 family proteins have been demonstrated to play a pivotal
role in regulating and executing the intrinsic apoptotic pathways
[24,25]. Therefore, we further investigated whether upregulation
of SPHK1 could affect the expression of Bcl-2 family proteins in
glioma cells. As shown in Figure 4A, the expression of Bcl-2, Mcl-1
or Bax was not altered in the SPHK1-overexpressing cells,
whereas the expression of BimEL was significantly decreased. The
other two major Bim isoforms, BimL and BimS, were undetectable
in the cell lines as similar to previous reports [26]. Real-time RT-
PCR was performed and found a consistent decrease in Bim
mRNA level in SPHK1-overexpressing cells as compared with the
vector-control (Figure 4B). In contrast, downregulation of SPHK1
significantly increased Bim expression at both protein and
transcription levels (Figures 4A and 4B).
To further delineate the correlation between SPHK1 and Bim
expression in glioma, we next examined clinical primary glioma
Figure 1. Glioma cells overexpressing SPHK1 protein are less sensitive to UV- or adriamycin-induced apoptosis. (A) Overexpression of
SPHK1 in glioma cell lines analyzed by WB. a-tubulin was used as a loading control. (B) SPHK1 enzymatic activity in SPHK1-overexpressed glioma cells
was markedly increased. (C) Overexpression of SPHK1 inhibited cell death induced by adriamycin (left panel) or UV irradiation (right panel). Seventy-
two hours after treatment with adriamycin or UV irradiation, cell viability was assessed by the trypan blue exclusion method. (D) SPHK1 prevented
adriamycin-induced apoptosis of glioma cells. Annexin-V binding and TUNEL assays of indicated cells were performed after incubation with
adriamycin for 6 h and 24 h, respectively. Quantification of TUNEL positive cells (left panel) and Annexin V
+/PI
2 cells (right panel). Results are
expressed as percentages of total cells. (E) PARP cleavage and cleaved caspase 3 levels were assessed in indicated cells treated with UV irradiation
(40 J/m
2) or adriamycin (1.0 mM) for 24 h via WB. a-tubulin was used as a loading control. For (B), (C) and (D), error bars represent mean 6 SD from
three independent experiments with similar results. *, p,0.05.
doi:10.1371/journal.pone.0019946.g001
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82 tumor cases examined, high levels of SPHK1 expression were
seen in 33 cases (40.2%), whereas 49 cases (59.8%) had low or
undetectable levels of SPHK1 expression (Figure 4C). It is
particularly noteworthy that 24 out of 33 (72.7%) glioma samples
that exhibited high SPHK1 expression displayed low expression of
Bim, in contrast to the high level Bim expression in 34 out of the
49 (69.4%) glioma samples with low SPHK1 expression
(Figure 4C). Furthermore, Spearman correlation analysis showed
that the correlation between SPHK1 and Bim expression was
statistically significant (p=0.021), suggesting a potential involve-
ment of Bim downregulation in SPHK1-induced anti-apoptotic
state in glioma.
FOXO3a activity was altered in SPHK1 overexpression or
downregulation glioma cells
To clarify the signal transduction pathways involved in
regulating the expression of Bim in response to alterations of
SPHK1 expression, the general expression level as well as
activation status of transcription factor FOXO3a, a well known
regulator of Bim [14], was examined in glioma cells with SPHK1
overexpressed or knocked down. As shown in Figure 5A, the
SPHK1-overexpressed U87MG and LN-382 cells exhibited
increased FOXO3a (Ser
253) phosphorylation, in contrast,
FOXO3a (Ser
253) phosphorylation decreased dramatically in
SPHK1-downregulated glioma cells. Furthermore, the luciferase
activities of the FOXO3a reporter were examined to delineate the
Figure 2. Downregulation of SPHK1 expression decreases the resistance of glioma cells to apoptosis. (A) SPHK1 knockdown was
achieved by introducing specific shRNAs in glioma cells. a-tubulin was used as a loading control. (B) Silencing of SPHK1 led to significant decrease of
enzymatic activity in glioma cells. (C) Knockdown of SPHK1 enhances cell death. (D) SPHK1 knockdown enhanced the sensitivity of glioma cells to
adriamycin-induced apoptosis. Quantification of TUNEL positive cells (left panel) and Annexin V
+/PI
2 cells (right panel). Results are expressed as
percentages of total cells. (E) PARP cleavage and cleaved caspase 3 levels were assessed in indicated cell lines treated with UV irradiation (40 J/m
2)o r
adriamycin (1.0 mM) for 24 h via WB. a-tubulin was used as a loading control. For (B), (C) and (D), error bars represent mean 6 SD from three
independent experiments with similar results. *, p,0.05.
doi:10.1371/journal.pone.0019946.g002
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shown in Figure 5B, overexpression of SPHK1 indeed significantly
reduced the activity of luciferase in the glioma cells, whereas the
transcriptional activity of FOXO3a was elevated significantly in
SPHK1 downregulated glioma cells, further suggesting that
SPHK1 expression attenuated gene transcription driven by
FOXO3a in glioma cells.
Since phosphorylation of FOXO3a was found to cause nuclear
exclusion and consequently, inhibition of its transcriptional
activity, we decided to examine whether SPHK1 modulated the
nuclear expression of FOXO3a. WB analysis and cellular
fractionation experiment showed that expression of FOXO3a in
the nuclei was markedly increased in SPHK1 knocked-down cells
and decreased in SPHK1 overexpressing cells (Figure 5C),
suggesting that SPHK1 inhibited FOXO3a transcription activity
through phosphorylation-dependent nuclear exclusion.
To further confirm the role of FOXO3a in regulating the
expression of Bim in response to alterations of SPHK1 expression,
we knocked down the expression of FOXO3a with specific siRNA
in SPHK1 downregulated glioma cells. As shown in Figure 5D,
SPHK1 knockdown-induced upregulation of Bim could be
reversed by silencing FOXO3a, suggesting that FOXO3a is an
important mediator of SPHK1-induced Bim expression.
SPHK1 downregulated FOXO3a transcriptional activity
via PI3K/Akt signaling
To elucidate the molecular mechanism via which SPHK1
regulates the activity of FOXO3a, the expression level and
phosphorylated status of FOXO3a were examined in SPHK1-
overexpressing and -knocked down glioma cells. Real time RT-
PCR analysis revealed that SPHK1 did not change FOXO3a
expression in transcriptional level (data not shown). WB analysis
showed that the total expression level of FOXO3a did not change
in glioma cells with SPHK1 overexpressed or knocked down,
whereas the phosphorylation level of FOXO3a was significantly
increased in SPHK1-transduced glioma cells as compared with
vector-control cells, and a dramatic reduction of phosphorylation
of FOXO3a was observed in SPHK1 knockdown cells (Figure 5A).
It was reported that phosphorylation of FOXO3a could be
mediated through activation of the Akt signaling pathway. Thus,
we were promoted to further examine whether deregulation of
SPHK1 could stimulate the activity of Akt kinase. As shown in
Figure 3. The effects of dysregulation of SPHK1 expression on epirubicin induced-apoptosis in vivo. (A) Tumor volumes were measured
on the indicated days. Left panel, indicated cells (2610
6) were injected in the flank of nude mice. When the mean tumor volume reached
approximately 50 mm
3, the mice were injected i.p. with epirubicin (5 mg/kg), every 3 days, up to 15 days. Right panel, U87MG-vector cells (2610
6)
were injected in the flank of nude mice. When the mean tumor volume reached approximately 50 mm
3, the mice were randomized into two groups
(n=5) and injected intraperitoneally either with epirubicin (Epi, 5 mg/kg) or epirubicin (Epi, 5 mg/kg) plus SK1-I (50 mg/kg) every 3 days, up to
15days. (B) Mean tumor weights were measured. Immunofluorescent images (C) and quantification (D) of TUNEL positive cells. For (B) and (D), error
bars represent mean 6 SD from three independent experiments with similar results *, p,0.05.
doi:10.1371/journal.pone.0019946.g003
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overexpression of SPHK1 and downregulated when SPHK1 was
knocked down in U87MG and LN-382 glioma cells, suggesting a
potential role of Akt in the signaling cascade that mediates
FOXO3a phosphorylation/inactivation in response to SPHK1
upregulation. To further confirm this observation, we inhibited the
PI3K activity by using its pharmacological inhibitor LY294002
and subsequently analyzed the levels of phosphorylated Akt,
phosphorylated FOXO3a and Bim. As shown in Figure 6A, both
phospho-Akt (Thr
308 and Ser
473) and phospho-FOXO3a (Ser
253)
were lowered after LY294002 treatment, while Bim protein level
was increased significantly, suggesting that the effect of SPHK1 on
FOXO3a phosphorylation was dependent on PI3K/Akt signaling.
Inhibition of SPHK1 kinase activity abrogated the effects
of SPHK1 on Akt/FOXO3a/Bim pathway in glioma cells
To further delineate the key role of SPHK1 in triggering the
activation of Akt/FOXO3a/Bim signaling cascade, the kinase
activity of SPHK1 was suppressed by SPHK1 inhibitor (SK-I) in
SPHK1-overexpressing glioma cells. As shown in Figure 6B,
SPHK1 inhibition decreased phosphorylation of Akt and
FOXO3a and upregulated Bim, an overall response similar to
RNAi knockdown of SPHK1. Taken together, this result, in
conjunction with other data obtained in the rest of this study,
identified SPHK1 as a trigger of the Akt/FOXO3a/Bim cascade.
Discussion
The key finding of our present study is represented by the
identification of a new chain of kinase reaction in glioma cells,
activated by upregulated SPHK1, sequentially causing phosphor-
ylated activation of Akt, phosphorylated inactivation of FOXO3a
and downregulation of Bim, and consequently leading to evasion
of glioma cells from programmed cell death or abrogation of
chemotherapeutic agents-induced apoptosis.
Evasion of apoptosis is a hallmark of most human tumors and
constitutes an important clinical problem. Many therapeutic
agents act against cancers through inducing apoptosis, and
resistance to cancer therapies usually involves intrinsic or extrinsic
abrogation of the apoptotic mechanism in cancer cells. Accumu-
lating evidences have indicated that SPHK1 could protect cancer
cells from apoptosis [27]. Therefore, understanding the molecular
mechanisms that mediate the anti-apoptotic effect of SPHK1 may
lay a foundation for new anti-cancer strategies. To this end, the
present study has for the first time provided a molecular dissection
Figure 4. The expression of Bim is correlated with SPHK1 in vitro and in vivo. (A) The expression of BimEL protein level was significantly
decreased in SPHK1 overexpression cells (left panel) and increased in SPHK1 knocked-down cells (right panel). (B) Overexpression of SPHK1
significantly decreased mRNA level of Bim (left panel), while knockdown of SPHK1 increased transcriptional level of Bim (right panel). (C) Examples of
Bim expression in correlation with SPHK1 in human primary glioma specimens. Left panel, IHC staining of SPHK1 and Bim in glioma. Right panel,
correlation of Bim and SPHK1 (n=82; p=0.021). Each data point represents one glioma specimen, and 24 of 33 (72.7%) glioma specimens with high
SPHK1 expression displayed low expression of Bim, whereas 34 of 49 (69.4%) glioma specimens that showed low SPHK1 expression exhibited high
expression of Bim. 0, no staining; 1, low staining; 2, moderate staining; 3, high staining.
doi:10.1371/journal.pone.0019946.g004
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down-regulation of Bim and consequent resistance to apoptosis.
Bim, a member of Bcl-2 family, is a pro-apoptotic protein
characterized by containing a single Bcl-2 homology 3 domain. In
line with previous studies [28,29], the expression of Bim appears to
be under the regulation of SPHK1in glioma cells. Furthermore,
overexpression of SPHK1 correlated with downregulation of Bim
in clinical glioma samples. Interestingly, induction of Bim
Figure 5. FOXO3a phosphorylation, transcriptional activity and Akt phosphorylation are regulated by SPHK1 in glioma cells. (A)
SPHK1 phosphorylates FOXO3a in glioma cells. (B) FOXO3a-dependent transcription activity is regulated by overexpression (left panel) or knockdown
(right panel) of SPHK1. Error bars represent mean 6 SD from three independent experiments with similar results. *, p,0.05. The GFP expression was
used to indicate the transfection efficiency. (C) WB analysis of nuclear FOXO3a protein in indicated cells. (D) SPHK1 knockdown-induced upregulation
of Bim could be reversed by silencing of FOXO3a in indicated glioma cells. (E) The phosphorylation status of Akt at Thr
308 and Ser
473 were assessed by
WB in SPHK1 overexpressed and knocked-down glioma cell lines.
doi:10.1371/journal.pone.0019946.g005
Figure 6. The effect of SPHK1 on Akt/FOXO3a/Bim pathway can be inhibited by PI3K inhibitor or SPHK1 inhibitor. U87MG-SPHK1 and
LN-382-SPHK1 cells were incubated with 50 mM LY294002 (A) or 5 mM SK-I (B) for 24 h and cell lysates were harvested and subjected to WB. phospho-
Akt (p-Akt), total Akt, p-FOXO3a, total FOXO3a and Bim were detected with specific antibodies, respectively.
doi:10.1371/journal.pone.0019946.g006
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chemotherapeutic agents such as lovastatin, anisomycin-caused
ribotoxic stress, or nitric oxide [30–32]. Thus, our finding provides
a new insight into a possible mechanism that underlies SPHK1
induced resistance of glioma cells to apoptosis.
It is of note that regulation of Bim protein is attributed to
transcriptional and posttranslational mechanisms [33]. One of the
transcription factors involved in modulation the expression of Bim
is a forkhead transcription factor, FOXO3a. Consistent with
previous findings [15,34–36], our study identifies FOXO3a as a
mediator of SPHK1-associated downregulation of Bim, based on
the following observations. Firstly, SPHK1 overexpression caused
FOXO3a phosphorylation, and SPHK1 knockdown caused
FOXO3a dephosphorylation in glioma cells. Secondly, pharma-
cological inhibitor of SPHK1 suppressed FOXO3a phosphoryla-
tion and increased Bim level. Thirdly, the transcriptional activity
of FOXO3a was regulated by the level of SPHK1 protein in
glioma cells.
It is evident that FOXO3a is under the regulation of the PI3K/
Akt pathway [37]. Akt seems to be essential in phosphorylating
FOXO3a in current study because our results showed activation of
Akt and Ser
253 phosphorylation of FOXO3a in SPHK1-
overexpressing glioma cells, as well as Akt inactivation and
Ser
253 dephosphorylation of FOXO3a in SPHK1-downregulated
glioma cells. The results of our study using LY249002 to suppress
PI3K further confirmed that activation of FOXO3a was
attributable to deregulation of PI3K/Akt signaling. Thus, data
obtained from the present investigation indicate that PI3K/Akt
signaling may play a role in mediating the regulation of FOXO3a
by SPHK1. Furthermore, studies have demonstrated that SPHK1
can activate the PI3K/Akt pathway in human cancers [19,38–42].
In glioma cells, as shown by our study, upregulated SPHK1
activates PI3K/Akt signaling and supports cell survival through
modulation of FOXO3a and Bim, representing a new mechanism
possibly underlying the development of glioma and probably, its
resistance to pro-apoptotic therapeutics. Nevertheless, mechanism
by which SPHK1 activates PI3K in glioma cells, i.e., via a direct
versus indirect interaction between two molecules, remains to be
determined. In this context, it is of note that sphingosine,
sphingosine 1-phosphate (S1P) and ceramide are inter-convertible
sphingolipids associated with numerous cell functions including
proliferation, apoptosis and migration [43]. It has been demon-
strated that Ceramide mediates and triggers cell growth arrest or
apoptosis by inactivating PI3K/Akt [44], whereas S1P enhances
proliferation and inhibits ceramide-mediated apoptosis [45,46].
Furthermore, SPHK1 is a key regulator of the ceramide/S1P
biostat since it is responsible for phosphorylating sphingosine, a
catabolite of ceramide, to form S1P [43]. One may postulate that
SPHK1-induced PI3K/Akt activation is attributable to decreased
levels of sphingosine and ceramide. Alternatively, another
possibility can be linked to extracellular S1P signaling via the
S1P1 G protein-coupled receptor, which activates Rac, Fak and
PI3K [47]. Further studies that aim at completely delineating the
interaction between SPHK1 and PI3K/Akt will help develop new
molecular targets for glioma therapy.
Treatment of glioma remains a clinical challenge. Currently
available therapeutic strategies against glioma generally only delay
local progression, and recurrence associated with resistance to
therapies largely contributes to the high mortality of the disease.
However, malignant glioma are typically infiltrative in nature.
Thus, gaining new insights into the mediators of the apoptotic
response in glioma will enable the development of novel anti-
tumor strategies. In this context, targeting SPHK1 or its
downstream signaling molecules as identified by our present study
might represent new and potential strategies against human
glioma.
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